No Detail Found!

Diabetes and its treatment by glucagon- like peptide 1 analogs and di-peptidyl peptidase 4 inhibitors

Author(s)
Owais Khan Medical students, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Rabeea Mirza Medical students, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Fuad Shaikh Department of Pharmacology, Dow University of Health Sciences, Karachi, Pakistan
Sadia Farooq Medical students, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Abstract
The burden of diabetic patients on healthcare has increased over the period of time. Management ofdiabetes presents a challenge to the physician. The availability of newer drugs, tested in high qualityclinical trials, has marked a new era in the treatment of diabetes. Glucagon-like peptide 1 (GLP-1)analogs act by increasing the pancreatic beta-cell mass and subsequent insulin secretion. Dipeptidase-4(DPP-4) inhibitors inhibit the enzyme that degrades GLP-1, resulting in the augmentation of GLP-1 in thebody. Hence, the two drugs can be used synergistically. It was seen that severe hypoglycemia seldomoccurred with GLP-1 analogues and DPP-4 inhibitors. Gastrointestinal upset and the development ofantibodies to the drug in the body was mainly attributed to GLP-1 analogs. DPP-4 inhibitors showedincreased risk of nasopharyngitis, urinary tract infections and headache.There is a need for further advances in our understanding, through randomized control clinical trials inlarger settings, to establish the role and safety of these newer agents in the treatment of diabetes. Theinitiation of a modern set of medications may help us control type2 diabetes better. 
Publication Details
Page(s) 286-290
DOI DOI not available
Published Journal: Journal of Postgraduate Medical Institute, Volume: 25, Issue: 4, Year: 2011

Request the full text from PASTIC

0

Citations

0

Downloads

56

Views